Journal Article

Prehospital Tranexamic Acid for Severe Trauma

Mitra, Biswadev, Dicker, Bridget, Murray, Lynnette J, Myles, Paul S, Young, Paul J, Hurford, Sally, Bernard, Stephen A, Trapani, Tony, Reade, Michael C, Gantner, Dashiell C, Gruen, Russell L, Forbes, Andrew B, Rashford, Stephen, Swain, Andrew H, Medcalf, Robert L, Maegele, Marc, Ng, Sze J, Burns, Brian, Mazur, Stefan M, Cameron, Peter A, McArthur, Colin J, Pitt, Veronica, Martin, Catherine A

2023

Overview

Whether prehospital administration of tranexamic acid increases the likelihood of survival with a favorable functional outcome among patients with major trauma and suspected trauma-induced coagulopathy who are being treated in advanced trauma systems is uncertain. We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1-g infusion over a period of 8 hours after arrival at the hospital) or matched placebo. The primary outcome was survival with a favorable functional outcome at 6 months after injury, as assessed with the use of the Glasgow Outcome Scale-Extended (GOS-E). Levels on the GOS-E range from 1 (death) to 8 (\"upper good recovery\" [no injury-related problems]). We defined survival with a favorable functional outcome as a GOS-E level of 5 (\"lower moderate disability\") or higher. Secondary outcomes included death from any cause within 28 days and within 6 months after injury. A total of 1310 patients were recruited by 15 emergency medical services in Australia, New Zealand, and Germany. Of these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned to receive placebo; the trial-group assignment was unknown for 3 patients. Survival with a favorable functional outcome at 6 months occurred in 307 of 572 patients (53.7%) in the tranexamic acid group and in 299 of 559 (53.5%) in the placebo group (risk ratio, 1.00; 95% confidence interval [CI], 0.90 to 1.12; P = 0.95). At 28 days after injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the placebo group had died (risk ratio, 0.79; 95% CI, 0.63 to 0.99). By 6 months, 123 of 648 patients (19.0%) in the tranexamic acid group and 144 of 629 (22.9%) in the placebo group had died (risk ratio, 0.83; 95% CI, 0.67 to 1.03). The number of serious adverse events, including vascular occlusive events, did not differ meaningfully between the groups. Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8 hours did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. (Funded by the Australian National Health and Medical Research Council and others; PATCH-Trauma ClinicalTrials.gov number, NCT02187120.).

• Publisher: Massachusetts Medical Society
• Subject: Acids / Adult / Antifibrinolytic agents / Antifibrinolytic Agents - adverse effects / Antifibrinolytic Agents - therapeutic use / Australia / Blood Coagulation Disorders - etiology / Blood pressure / Body temperature / Clinical Medicine / Clinical Medicine General / Coagulation / Consent / Critical Care / Emergency Medical Services / Emergency Medicine / Emergency Medicine General / Glasgow Coma Scale / Head Trauma / Hematology / Humans / Medical research / Neurology / Neurosurgery / Oncology / Patients / Placebos / Pulmonary / Statistical analysis / Surgery / Surgery General / Survival / Thrombosis / Tranexamic Acid - adverse effects / Tranexamic Acid - therapeutic use / Trauma / Traumatic brain injury / Vascular Diseases - etiology / Wounds and Injuries - complications